The Health Ministry has denied claims that it overspends on innovator drugs compared to generics, stressing that procurement decisions are guided by medical necessity and cost-effectiveness.
Health Ministry Defends Drug Procurement Strategy Amid Cost Concerns
Officials said drug selection depends on clinical requirements, treatment outcomes, and patient safety considerations, rather than price alone. Generics are used where appropriate, but certain cases require specialised or patented medications.
The ministry reaffirmed its commitment to transparent and efficient healthcare spending, amid ongoing scrutiny over rising medical costs. Authorities emphasised that balancing affordability and treatment quality remains a key priority.
Follow us on:
Read More News at #latestmalaysia #BusinessNews and #WorldFuture
